Assistant Professor of Medicine
Member of the Duke Cancer Institute
Campus mail
Dept of Medicine, Box 31379 Med Ctr, Durham, NC 27710
Phone
(919) 684-8111
Email address
jeffrey.clarke@duke.edu
Education and Training
- Internal Medicine Chief Resident, Medicine, Duke University School of Medicine, 2012 - 2013
- Hematology and Medical Oncology Fellowship, Medicine, Duke University School of Medicine, 2011 - 2015
- Categorical Internal Medicine Residency, Medicine, Duke University School of Medicine, 2008 - 2011
- M.D., Indiana University, School of Medicine, 2008
Grants
- An Open-Label, Multi-Center Phase I/IIa Study Evaluating the Safety and Clinical Activity of Neoantigen Reactive T cells in Patients with Advanced Non-Small Cell Lung Cancer (CHIRON)
- Chemotherapy and Atezolizumab for Patients with Extensive Stage Small Cell Lung Cancer (SCLC) with Untreated Brain Metastases (HCRN-LUN19-247)
- Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer
- Prospective collection of donor tissue and blood or leukapheresis product from patients with solid tumours to enable development of methods for the manufacturing of clonal neoantigen T cell products (cNeT).
- A Phase 1b Study Evaluating the Safety and Tolerability, and Efficacy of AMG510 in Combination with Everolimus
- Phase Ib First in Human Dose Escalation of GT103 in Refractory, Advanced Stage Non-Small Cell Lung Cancer (TOP 1902)
- A Phase 1b/2a Pilot Randomized Study to Evaluate the Safety andTolerability of Autologous T-Cells Expressing Enhanced TCRs (T-Cell Receptors) Specific for NY-ESO-1/LAGE-1a (GSK3377794) Alone, or in Combination with Pembrolizumab in HLA-A2+ Participa
- A Phase 2, Open-label Study of Encorafenib + Binimetinib in Patients with BRAF V600E-mutant Non-small Cell Lung Cancer
- Radiation and Chemotherapy with Ipilimumab followed by Nivolumab for Patients with Stage III Unresectable NSCLC
- A Phase II Clinical Trial of Combination Nivolumab (Opdivo), Ipilimumab (Yervoy), and Taxane in Patients with Untreated Metastatic Non-Small Cell Lung Cancer (NSCLC) (The OPTIMAL Trial)
- Duke-UNC-Wash U Partnership for Early Phase Clinical Trials in Cancer
- A screening protocol to determine tumor antigen expression and HLA sub-type ofr eligibility determination for clinical trials evaluating the safety and efficacy of Autologous T Cell expressing enhance
- A Phase 1, Open-Label, Multicenter Study to Assess the Safety, Tolerability, and Immunogenicity of mRNA-4157 Alone in Subjects with Resected Solid Tumors and in Combination with Pembrolizumab in Subjects with Unresectable Solid Tumors
- A Phase 2 Study of Poziotinib in Patients with Non-Small Cell Lung Cancer, Locally Advanced or Metastatic, with EGFR or HER2 Exon 20 Insertion Mutation (POZITIVE20-1)
- Adaptimmune SURPASS
- CBMG NSCLC Tumor Specimens for TIL Cell Therapy
- Cell-Free DNA for Diagnosis of Malignancy, Genetic Mutations and Prognosis in Lung Cancer Related Pleural Effusions
- Race-related differential RNA splicing: novel targets for precision oncology in non-small cell lung cancer
- "Understanding the Patient Experience of Stage 3 Unresectable Non-Small Cell Lung Cancer (NSCLC) in the Immuno-oncology Era"